Imperial College London
Alternate

Emeritus ProfessorDavidWood

Faculty of Medicine, National Heart & Lung Institute

Emeritus Professor in Cardiology
 
 
 
//

Contact

 

d.wood

 
 
//

Location

 

Guy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Morbach:2017:10.1186/s12872-017-0543-0,
author = {Morbach, C and Wagner, M and Guntner, S and Malsch, C and Oezkur, M and Wood, DA and Kotseva, K and Leyh, R and Ertl, G and Karmann, W and Heuschmann, PU and Stork, S},
doi = {10.1186/s12872-017-0543-0},
journal = {BMC Cardiovascular Disorders},
title = {Heart failure in patients with coronary heart disease: Prevalence, characteristics and guideline implementation – Results from the German EuroAspire IV cohort},
url = {http://dx.doi.org/10.1186/s12872-017-0543-0},
volume = {17},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Adherence to pharmacotherapeutic treatment guidelines in patients with heart failure (HF) is of majorprognostic importance, but thorough implementation of guidelines in routine care remains insufficient. Our aimwas to investigate prevalence and characteristics of HF in patients with coronary heart disease (CHD), and to assessthe adherence to current HF guidelines in patients with HF stage C, thus identifying potential targets for theoptimization of guideline implementation.Methods: Patients from the German sample of the European Action on Secondary and Primary Prevention byIntervention to Reduce Events (EuroAspire) IV survey with a hospitalization for CHD within the previous six to36 months providing valid data on echocardiography as well as on signs and symptoms of HF were categorizedinto stages of HF: A, prevalence of risk factors for developing HF; B, asymptomatic but with structural heart disease;C, symptomatic HF. A Guideline Adherence Indicator (GAI-3) was calculated for patients with reduced (≤40%) leftventricular ejection fraction (HFrEF) as number of drugs taken per number of drugs indicated; beta-blockers,angiotensin converting enzyme inhibitors/angiotensin receptor blockers, and mineralocorticoid receptor antagonists(MRA) were considered.Results: 509/536 patients entered analysis. HF stage A was prevalent in n = 20 (3.9%), stage B in n = 264 (51.9%),and stage C in n = 225 (44.2%) patients; 94/225 patients were diagnosed with HFrEF (42%). Stage C patients wereolder, had a longer duration of CHD, and a higher prevalence of arterial hypertension. Awareness of pre-diagnosedHF was low (19%). Overall GAI-3 of HFrEF patients was 96.4% with a trend towards lower GAI-3 in patients withlower LVEF due to less thorough MRA prescription.Conclusions: In our sample of CHD patients, prevalence of HF stage C was high and a sizable subgroup sufferedfrom HFrEF. Overall, pharmacotherapy was fairly well implemented in HFrEF patients, although somewhat worse inp
AU  - Morbach,C
AU  - Wagner,M
AU  - Guntner,S
AU  - Malsch,C
AU  - Oezkur,M
AU  - Wood,DA
AU  - Kotseva,K
AU  - Leyh,R
AU  - Ertl,G
AU  - Karmann,W
AU  - Heuschmann,PU
AU  - Stork,S
DO  - 10.1186/s12872-017-0543-0
PY  - 2017///
SN  - 1471-2261
TI  - Heart failure in patients with coronary heart disease: Prevalence, characteristics and guideline implementation – Results from the German EuroAspire IV cohort
T2  - BMC Cardiovascular Disorders
UR  - http://dx.doi.org/10.1186/s12872-017-0543-0
UR  - http://hdl.handle.net/10044/1/53995
VL  - 17
ER  -
Download